Stroke recurrence in children with sickle cell disease treated with hydroxyurea following first clinical stroke
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Chronic transfusion therapy is the treatment of choice for preventing stroke recurrence in children with sickle cell disease (SCD). The majority of children affected by this devastating complication live in the developing world where access to regular blood transfusions may be impractical. Since 2000, in the absence of regular blood supplies, all children at the Sickle Cell Unit who had experienced a first clinical stroke were offered hydroxyurea (HU) as the only intervention to prevent stroke recurrence. Forty‐four children were identified as having experienced a first clinical stroke between January 1, 2000 and September 30, 2009; one died at that presentation. Forty‐three children were therefore followed for 111 person‐years, of whom 10 (23.3%) agreed to start HU. Only one child in the HU group, incidence rate 2/100 person‐years, had clinical stroke recurrence, compared to 20/33 in the non‐HU group, incidence rate 29/100 person‐years (Hazard ratio (HR) 9.4 [95% Confidence interval (CI): 1.3–70.6];P= 0.03). When the groups were compared, in the non‐HU group, four died (vs. zero), 13 (53% vs. 10%) had moderate–severe physical disability (P= 0.017), and 12 (44% vs. 20%) required special education or were too disabled to attend school. Our data support the role of HU as a useful intervention for prevention of stroke recurrence in SCD when transfusion programs are not available or practical. Am. J. Hematol., 2011. © 2011 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mortality in sickle cell disease. Life expectancy and risk factors for early death
Platt, O. S., Brambilla, D. J., Rosse, W. F., Milner, P. F., Castro, O., Steinberg, M. H., & Klug, P. P. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406093302303 · Cited by 3,320 · cited 1×
“Introduction Sickle cell disease (SCD) is an inherited hemoglobinopathy characterized by chronic hemolytic anemia, a vasculopathy leading to hypoxic-ischemic tissue injury and ultimately decreased life expectancy [1].”
BackgroundCerebrovascular accidents in sickle cell disease: rates and risk factors.
(1998) · PubMed · doi:10.1182/blood.v91.1.288 · Cited by 1,694
Discontinuing Prophylactic Transfusions Used to Prevent Stroke in Sickle Cell Disease
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa050460 · Cited by 635
The natural history of stroke in sickle cell disease
Powars, D., Wilson, B., Imbus, C., Pegelow, C., & Allen, J. (1978) · The American Journal of Medicine · doi:10.1016/0002-9343(78)90772-6 · Cited by 594 · cited 2×
“Untreated, up to 20% of affected patients will die within 7 months of their first stroke, 56% by the time they are 20 years old [11].”
BackgroundStroke in a cohort of patients with homozygous sickle cell disease
Balkaran, B., Char, G., Morris, J. S., Thomas, P. W., Serjeant, B. E., & Serjeant, G. R. (1992) · The Journal of Pediatrics · doi:10.1016/s0022-3476(05)80897-2 · Cited by 419
Bernaudin, F., Verlhac, S., Arnaud, C., Kamdem, A., Chevret, S., Hau, I., Coïc, L., Leveillé, E., Lemarchand, E., Lesprit, E., et al. (2011) · Blood · doi:10.1182/blood-2010-06-293514 · Cited by 336
Dobson, S. R., Holden, K. R., Nietert, P. J., Cure, J. K., Laver, J. H., Disco, D., & Abboud, M. R. (2002) · Blood · doi:10.1182/blood.v99.9.3144 · Cited by 277
Cited by
Kernan, W. N., Ovbiagele, B., Black, H. R., Bravata, D. M., Chimowitz, M. I., Ezekowitz, M. D., Fang, M. C., Fisher, M., Furie, K. L., Heck, D. V., et al. (2014) · Stroke · doi:10.1161/str.0000000000000024 · Cited by 5,170
Kleindorfer, D. O., Towfighi, A., Chaturvedi, S., Cockroft, K. M., Gutierrez, J., Lombardi-Hill, D., Kamel, H., Kernan, W. N., Kittner, S. J., Leira, E. C., et al. (2021) · Stroke · doi:10.1161/str.0000000000000375 · Cited by 3,237
Belisário, A. R., Sales, R. R., Toledo, N. E., Muniz, M. B. D. S. R., Velloso-Rodrigues, C., Silva, C. M., & Viana, M. B. (2016) · Annals of Hematology · doi:10.1007/s00277-016-2789-5 · Cited by 29
Metadata
- Authors
- Ali, S. B., MooSang, M., King, L., Knight‐Madden, J., & Reid, M.
- Venue
- American Journal of Hematology
- Publisher
- Wiley
- Published
- 2011-09-02
- Volume
- 86
- Issue
- 10
- Pages
- 846-850
- ISSN
- 0361-8609 (ISSN-L)
- 1096-8652
- OpenAlex
- W2062915958
- Cited by
- 50
- References
- 7
- FWCI
- 2.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.